4//SEC Filing
Kalif Eliyahu Sharon 4
Accession 0000950170-24-025888
CIK 0000818686other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 4:08 PM ET
Size
13.3 KB
Accession
0000950170-24-025888
Insider Transaction Report
Form 4
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2024-03-03+49,800→ 174,022 total - Exercise/Conversion
Ordinary Shares
2024-03-04+33,512→ 207,534 total - Exercise/Conversion
Restricted Share Units
2024-03-03−49,800→ 174,022 total→ Ordinary Shares (49,800 underlying) - Exercise/Conversion
Restricted Share Units
2024-03-04−33,512→ 207,534 total→ Ordinary Shares (33,512 underlying) - Award
Restricted Share Units
2024-03-04+93,005→ 93,005 total→ Ordinary Shares (93,005 underlying)
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]Restricted share units were granted on March 3, 2023, with 49,800 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 49,802 vesting on March 3, 2027.
- [F4]Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026.
- [F5]Restricted share units were granted on March 4, 2024, with 23,251 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001798443
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 4:08 PM ET
- Size
- 13.3 KB